Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma
NCT07514767
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Oral Squamous Cell Carcinoma (OSCC)
Interventions
DRUG:
Nivolumab (240 mg)
Sponsor
Prof. Lars Olaf Cardell